ACR
American made between children who present with fewer than five joints in the first 6 months of disease but progress to follow a polyarticular course. The ILAR classification scheme also contains exclusion criteria for each class, with the largest number of exclusions in the oligoarthritis subtype. Family histories of psoriasis or HLA-B27 associated disease, a positive rheumatoid factor, systemic arthritis, or being an HLA-B27-positive male patient with onset of arthritis after 8 years of age exclude a patient from the oligoarthritis subtype [7] . An interesting commentary about the evolution and need for this classification scheme has recently been published [8•].
It is not clear whether this new classification scheme will be an improvement over ones currently in use. One attempt to apply the ILAR system to existing pediatric arthritis databases was presented by Foeldvari and Bidde [9] . These authors successfully classified 88% (85/97) of their study group into ILAR subtypes. Twelve percent (12/97) of their patients were classified as "other," half due to a family history of psoriasis (but not meeting criteria for psoriatic arthritis) and half because they met criteria for two subtypes. This retrospective analysis of one pediatric practice demonstrates some of the limitations of the ILAR classification scheme. Additional problems include arbitrary clinical criteria such as onset before the age of 16 years, symptom duration greater than 6 weeks, and the distinction between polyarticular and oligoarticular arthritis at four joints. None of these basic assumptions are likely to have true biologic correlates. These issues and others are put forth by Southwood [10] .
The ILAR proposal is an important change in classification for two reasons: (1) it begins to consolidate disparate classification schemes (allowing international communication to improve), and (2) it attempts to separate a heterogeneous group of patients into more homogeneous subtypes. There are a number of problems with this approach. Most significantly, the ILAR classification scheme remains one based on clinical characteristics rather than on underlying pathophysiology. Although it is tempting to speculate that similar patient populations have similar underlying causes, this may not actually be the case; in fact, the reverse may be true. Rather than helping find the underlying causes of childhood arthritis, use of the ILAR classification scheme may actually ob-scure them. Additional problems include the fact that the ILAR classification is not universally accepted and has not been scientifically validated. The lack of universally accepted criteria for other causes of arthritis in children, including spondyloarthropathies, psoriatic arthritis, inflammatory bowel disease arthritis, or reactive arthritis further complicates the issue.
Frustratingly, JIA remains a clinical diagnosis and attempts to uncover biologic markers that would facilitate classification have been disappointing. For example, Murray et al. [11] reported that antibodies to the 45 kD DEK protein were characteristic of pauciarticular onset JRA (ACR criteria), particularly in patients with a history of iridocyclitis, suggesting that anti-DEK antibodies might convey important prognostic information. However, a more recent look at anti-DEK antibodies indicated that they might be much less specific for juvenile arthritis than originally believed, occurring in many systemic autoimmune diseases [12] . Furthermore, no association was found between the presence of anti-DEK antibodies and the development of iridocyclitis. The possible role of anti-DEK antibodies as both a marker for disease as well as a possible pathophysiologic agent remains to be further elucidated.
Another disappointing avenue of research has been studies involving rheumatoid factor (RF). The limitations of using RF for classification have been shown by Varbanova et al. [13] . These authors found IgM RFs in juvenile arthritis patients with "seronegative" polyarticular and pauciarticular disease using an enzyme-linked immunosorbent assay. IgM-RF showed a prevalence of 55% in patients with polyarticular onset disease, 42% in patients with extended pauciarticular disease, 5% of patients with pauciarticular disease, and in no healthy controls. The researchers suggested that the presence of RF is partly dependent upon the type and sensitivity of the assay as opposed to underlying pathophysiology. These data support, however, the distinction between persistent oligoarthritis versus extended oligoarthritis [13] . Bharadwaj et al. [14] looked at the clinical relevance of IgA rheumatoid factor (IgA-RF) in children with JRA (by ACR criteria). Only when the cut-off value for a "positive" test was raised to 6 SDs above controls did the seroprevalence of IgA-RF in patients with polyarticular onset became significantly higher than that found in both pauciarticular onset and systemic onset [14] . These studies show that classifying patients as RF-positive or RF-negative is artificial and dependent upon the type of assay used, as well as the standardization within a given assay. Here again, classifying children with arthritis based on RFs may be a confounding variable, rather than providing insight into the pathogenesis. To date, a biologic marker that helps classify patients with juvenile arthritis has not been elucidated.
Clinical presentation and disease course
Important work continues to be performed on very fundamental aspects of juvenile arthritis, specifically with regard to its presentation and ultimate outcome. Sharma and Sherry [5] retrospectively reported on 215 children with pauciarticular arthritis (ACR criteria), finding that the most frequently affected joints were knees, ankles, fingers, toes, wrists, elbows, and hips, respectively, with 58% of the children having only one joint affected. Antinuclear antibodies (ANA) were present in 68% of patients and uveitis in 16% [5] . The ANA was positive in 91% of the patients who had uveitis, further supporting the widely held view that an ANA-positive child with oligoarthritis requires careful observation for uveitis. In a more recent longitudinal study of 207 patients with oligoarticular-onset JIA, however, the presence or absence of a positive ANA was found not to be predictive of uveitis (P = 0.56) [4] . These findings suggest that all children with oligoarticular JIA should be frequently screened for uveitis, regardless of ANA status [4] . Future studies will need to address this important issue.
Guillaume et al.
[4] examined long-term outcome and predictors of severity among 207 children with oligoarticular-onset JIA. At 6-year follow-up, 50% of children had progressed to polyarticular disease with joint erosions present in 35% and uveitis in 30%. Only 23% were in remission. The presence of joint destruction on radiographs was highly correlated with extension of disease and an elevated erythrocyte sedimentation rate. Additional predictors of extension to a polyarticular course included involvement of more than one joint and involvement of at least one joint in the upper extremity. This study raises the concern that oligoarticular-onset JIA may be more severe than previously described.
Although some subtypes of juvenile arthritis may be selflimited, many children experience painful complications such as joint destruction and deformity, osteoporosis, and growth abnormalities, which continue into adulthood. Zak and Pedersen [15] described 65 adults with juvenile chronic arthritis an average of 26.4 years after onset. Active disease was present in 37% of the study group, of which 80% had either extended pauciarticular or polyarticular juvenile arthritis. As might be expected, disease duration was the parameter most strongly associated with an unfavorable outcome. Another retrospective study of 80 consecutive patients with systemic onset JRA followed for 10 years demonstrated that 57.5% were found to be in remission at their last clinic visit [16] . Again, cumulative duration of disease correlated with a worse functional class. This provides further incentive for early diagnosis and aggressive early treatment to prevent a prolonged disease course.
The chronicity of juvenile arthritis has many important implications for growth. Although complications (eg, poor linear growth, osteoporosis, and leg length discrepancies) are commonly discussed, the importance of dental maturity and masticatory function in children with JIA has sometimes been overlooked. Recently, Harper et al. [17] compared the masticatory function of children with juvenile arthritis, with and without temporomandibular joint disorder, to healthy children. Children with juvenile arthritis had compromised masticatory function in comparison with the control group, causing the authors to speculate that this was a pain avoidance mechanism. As suggested by the authors, children may not complain of pain because they have already made compensatory changes in masticatory function to avoid pain, with consequent poorer nutrition. Lehtinen et al. [18] demonstrated that children with juvenile arthritis had advanced dental maturity compared with normal controls. Although it was not a significant finding, the authors pointed out that children treated with cortisone tended to have a more advanced dental maturity compared with those not treated with cortisone. Walton et al. [19] recently reviewed oral health and JIA, including discussion of the three main areas where JIA impacts oral health: dental caries, effects of medications, and temporomandibular joint disorder problems.
Plain radiographic films remain important in documenting the progression of active disease. Without reliable predictors of poor outcome early in disease course to help with therapeutic decisions, earlier evidence of joint destruction could prompt more timely initiation of second line agents. Magnetic resonance imaging (MRI) continues to show much promise in revealing early joint destruction, as reviewed by Lamer and Sebag [20] . Although not currently in widespread use, MRI represents an excellent method of determining the presence and extent of JIA, as well as following disease progression. Further studies are needed to examine whether MRI can be used to document early response to therapy.
Pathophysiology
Although there has been frustratingly little improvement in the classification of juvenile arthritis and markers of its activity, the study of the underlying pathophysiology of the disease continues to be an exciting area for research and therapy development. The role of cytokines as well as dynamic interactions between pro-inflammatory agents and anti-inflammatory agents within the joint continues to unfold. This has resulted in the successful development of new biologic agents, such as etanercept, that target specific inflammatory mediators.
A concise review of the role of cytokines in the pathogenesis of adult arthritis was recently published in the New England Journal of Medicine [21•]. In brief, rheumatoid arthritis is characterized by the destruction of bone and cartilage secondary to an increased inflammatory response. CD4+ T cells invade synovium and stimulate inflammatory cells. These inflammatory cells, such as macrophages, generate inflammatory cytokines including interleukin (IL)-1, IL-6, and tumor necrosis factor-␣ (TNF-␣). The cytokines then stimulate the release of proteinases, which are thought to lead to joint damage. In addition, TNF can stimulate the expression of adhesion molecules on endothelial cells and increase recruitment of neutrophils into joints (which subsequently release additional proteinases and cause further destruction). Cytokines are also important in the transmission of pain, as they can activate or sensitize C fibers. Despite improvements in understanding the cytokine profiles in patients with arthritis, the inciting events remain unclear.
One of the more exciting chapters in the story of the pathophysiology of JIA is the role TNF plays in joint inflammation. The development of therapeutic agents directed against TNF-␣ represents classic "bench to bed" translational biomedical research. TNF is well known to promote inflammation and recent work supports its importance in the pathogenesis of JIA. Rooney et al. [22] demonstrated that an imbalance between TNF-␣ and its soluble receptor might contribute to disease severity. Synovial fluid TNF-␣ and soluble tumor necrosis factor receptor (sTNFR) were measured. The sTNFR/TNF-␣ molar ratio was significantly higher in children with spondyloarthropathy compared with those with pauci-and polyarticular disease (with no significant differences between polyarticular and pauciarticular disease). The authors speculated that the molar excess of TNF receptor in spondyloarthropathy might curtail the effects of TNF-␣ (and result in less joint destruction).
Although TNF is only one of many cytokines involved in the development of arthritis, this study begins to examine the importance of dynamic interactions between a proinflammatory agent and the mechanisms used to regulate it. It also provides further evidence that different subtypes of JIA are truly different diseases with different cytokine profiles.
In a study by Harjacek et al. [23] , in situ hybridization was used to determine the expression of mRNA for proinflammatory or anti-inflammatory synovial cytokines in five patients with early, untreated JRA and with 15 patients with late, treated JRA. These authors showed that 8% of inflammatory cells in a synovial analysis in patients with early, untreated JRA expressed mRNA for the proinflammatory cytokine IL-1. In all, 3.9% of the cells expressed mRNA for the anti-inflammatory cytokine IL-10. Patients with late, treated disease had 0.8% of cells expressing proinflammatory IL-1, with anti-inflammatory expression less frequent. These data further support the importance of dynamic interactions between proand anti-inflammatory cytokines. As might be expected, juvenile arthritis patients appear to produce predominately pro-, and not anti-inflammatory, cytokine mRNA.
Other pathogenic mechanisms have been reported. Frosch et al. [24] demonstrated that myeloid-related protein 8 (MRP8) and myeloid-related protein 14 (MRP14) were released from activated monocytes combined with tumor necrosis factor-stimulated endothelial cells. These particular proteins were studied because earlier work had demonstrated their expression in inflammatory conditions. The authors proposed that the release of MRP8 and MRP14 induces adhesion of infiltrating cells to the vascular endothelium, leading to increased disease [24] . In patients with juvenile arthritis, these proteins were strongly expressed in infiltrating neutrophils and monocytes within inflamed joints. Furthermore, levels of MRP8 and MRP14 were present in significantly higher concentrations in synovial fluid compared with serum [24] . However, serum concentrations correlated with synovial fluid levels, indicating that serum concentrations could be used as markers for monitoring joint inflammation. This is an important observation, because it may indicate that a simple peripheral blood test can be used to follow the progression of joint disease. As suggested by the authors, MRP levels might be used to facilitate titration of therapy (such as blockers of TNF). Concentrations of MRP8 and MRP14 were found to be up to five times higher in serum samples from patients with active disease compared with those in remission. Children in remission, in fact, had levels that were only slightly higher than those found in normal control subjects [24] .
Additional work examined the role of chemokine receptors in JIA. Wedderburn et al. [25] recently studied the chemokine receptors CCR5 and CXCR3 in children with JIA. These receptors are expressed on activated T cells with a type 1 (Th1) cytokine profile (cells which are characterized by the production of proinflammatory cytokines such as interferon, TNF, and IL-2). The number of T cells that were CCR5+ and CXCR3+ was higher in synovial fluid than in peripheral blood and increased proinflammatory cytokine production was noted in the synovial T cells compared with peripheral blood T cells. Although previously shown in adult patients with rheumatoid arthritis, the study by Wedderburn and colleagues is one of the first to demonstrate a Th1 phenotype in children with chronic arthritis. As the authors suggest, expression of these chemokine receptors may result in selective recruitment of Th1-type T cells to the inflamed joints of children with JIA.
The role of growth factors and complement in the pathophysiology of juvenile arthritis continues to be examined. Maeno et al. [26] demonstrated that serum levels of vascular endothelial growth factor (VEGF) in children with juvenile arthritis were significantly higher than in healthy controls. Interestingly, serum VEGF levels correlated with disease activity variables such as the number of joints with active arthritis and erythrocyte sedimentation rate in children with polyarticular JRA. The authors speculate that the correlation of serum VEGF levels with disease activity may indicate that VEGF takes an active part in joint inflammation [26] . The relation of VEGF to joint destruction requires further investigation, but may be related to increased vascular permeability within the synovium.
Aggarwal et al. [27] pursued the role of complement in juvenile arthritis. These researchers recently reported that complement activation in juvenile arthritis is initiated predominantly by the alternative pathway. Further work performed by members of this group involved the role of IgM and IgA rheumatoid factors (IgM-RF and IgA-RF, respectively) [28] . In the latter study, there was evidence of increased circulating immune complexes in children with JRA compared with control subjects. Levels of C3d, but not of IgM-RF or IgA-RF, had a linear correlation with circulating immune complexes, leading the authors to speculate that circulating IgM-RF and IgA-RF have little role in complement activation in children with JRA [28].
Treatment
Methotrexate (MTX) continues to be the main secondline agent for most pediatric rheumatologists. Over the past 2 years, however, an amazing amount of work has been performed on newer agents, such as the TNF factor antagonist etanercept. These, and other, treatments for JIA are discussed at length below. Systemic corticosteroids are avoided when possible, but will sometimes be used for disease exacerbations. Chronic therapy with systemic corticosteroids raises concerns about growth retardation and osteoporosis, as well as weight gain and immune suppression. Perez et al. [29] studied calcium metabolism and bone mineral density in 13 children with early JIA treated with corticosteroids or nonsteroidal anti-inflammatory drugs. One year after diagnosis, the two groups did not differ significantly in measures of calcium metabolism, although there was a trend toward decreased bone mineralization in the steroid treated subjects. More long-term studies are obviously needed. Intra-articular corticosteroids remain a safe alternative to manage inflammation in a child with monoarticular or oligoarticular arthritis. It is also reasonable to use intra-articular corticosteroids in symptomatic joints in a child with polyarticular arthritis.
Biologic agents
The most exciting recent advances in the therapy of JIA are also an example of successful translational research. Etanercept is a genetically engineered fusion protein consisting of two identical chains of the recombinant human TNF-receptor p75 monomer fused with the Fc domain of human IgG1. It binds and inactivates TNF. With laboratory evidence showing that TNF-␣ is important in the inflammatory response and in the pathophysiology of arthritis, it was a logical step to extend this benchwork to the clinic.
First tested in adults with persistently active rheumatoid arthritis, etanercept was shown to be well tolerated, safe, and effective, providing significantly greater benefit than MTX alone [30] . At 24 weeks, 71% of patients receiving etanercept (versus 27% with placebo) reached the target clinical outcome. Adverse effects were mild, limited mainly to injection site reactions. An additional 1-year study comparing etanercept with MTX in adult patients with early rheumatoid arthritis indicated that etanercept acted more rapidly to decease symptoms and slow joint damage [31] .
These results have now been extended to include children with polyarticular juvenile rheumatoid arthritis [32•]. Lovell et al. [32•] examined a group of children who did not tolerate or respond to MTX. In this group, 74% of patients responded to etanercept, with an improvement in 30% or more of at least three of six indicators of disease activity at the end of the open-label component of the study. In the double-blind component of this study, patients who responded to treatment were randomized to either placebo or etanercept for 4 months or until a disease flare occurred. Eighty-one percent of placebo patients withdrew because of disease flare, whereas only 28% of etanercept-treated children withdrew (P = 0.003). The median time to flare was more than 116 days for children receiving etanercept and 28 days for those on placebo. There were no significant differences between the two treatment groups in the frequency of adverse reactions. The most common adverse reaction, as demonstrated previously, was injection site reactions. This is an important study, because it shows the efficacy and safety of etanercept in children. The study design, however, limits interpretation and further studies are currently ongoing in children.
Another way to block the effects of TNF includes treatment with chimeric anti-TNF-␣ monoclonal antibody (infliximab). Maini et al. [33] demonstrated that infliximab plus MTX was more efficacious than MTX alone. In this international double-blind placebo-controlled phase III clinical trial, 428 patients which active rheumatoid arthritis were randomized to placebo or infliximab for 30 weeks. A statistically significant improvement was noted in approximately 50% of the patients treated with infliximab, compared with 20% of the patients receiving placebo plus MTX. The drug was well tolerated, with only two patients (of 340) discontinuing because of an infusion reaction. This study was limited to adults, and included patients with aggressive disease. Lipsky et al. [34] also demonstrated that patients with persistently active rheumatoid arthritis (despite MTX therapy) had clinical improvement and no further joint damage when infliximab was added to MTX (51.8% responding vs 17%). No studies have been done in children with JIA, although there is information about the use of infliximab in children with inflammatory bowel disease. As with etanercept, it would be interesting to see what effect on disease progression would occur if TNF blockade were initiated earlier in the disease course. The long-term effect of TNF blockade continues to be an unanswered question.
Remittive agents
The antimetabolite MTX has long been used as a second-line agent in juvenile arthritis [35] . Recently its usefulness in the extended oligoarticular subtype was tested. Woo et al.
[36] performed a multicenter, doubleblind, placebo-controlled crossover trial enrolling 45 children with either systemic or oligoarticular arthritis treated with MTX (15-20 mg/m 2 /wk) or placebo. Children with both extended oligoarthritis and systemic arthritis improved; however, the children with oligoarticular extended disease improved on more parameters. Side effects were similar between MTX and placebo treatments [36] . Similar results were reported by Ravelli et al.
[37], who evaluated 80 patients, 6 months after initiation of therapy. The extended oligoarticular subtype predicted both short-term clinical response and complete disease control. These patients also tended to have earlier and more frequent relapses after MTX discontinuation. These data provide support that the extended oligoarticular subtype of patients may benefit more from treatment with MTX than other groups. In another nonrandomized, noncontrolled study, Ravelli et al. [38] reported that low-dose MTX (7.5 to 10.8 mg/m 2 /wk) appeared to alter the radiologic progression of disease as measured by carpal length in 16/26 children after 2 years of therapy. Another small study supports the use of MTX in children with resistant chronic uveitis [39] . Small sample size, lack of randomization, and no controls limit both studies.
A recent 24-week randomized, placebo-controlled, double-blind, multicenter study of patients with active juvenile arthritis of either oligoarticular or polyarticular onset was performed using sulfasalazine (SSZ) (50 mg/kg daily of SSZ or placebo). In an intention-to-treat analysis, SSZ treatment resulted in improvement in severity score, all global assessments, and laboratory parameters [40] . Although all adverse effects were reversible after discontinuation of treatment, SSZ was poorly tolerated in one third of children [40] . Gastrointestinal problems were the most prevalent adverse reaction.
A small, uncontrolled, retrospective chart review of 24 patients demonstrated that 15 (62.5%) showed clinical improvement and 9 (37.5%) demonstrated clinical remission when azathioprine therapy was added to their regimen [41] . In addition, more than 50% of children treated had a reduction in steroid use. Two children had significant side effects (pancytopenia and disseminated infection, which resolved with a dose correction). Further studies need to be performed to determine the efficacy of this drug, as well as possible long-term side effects (ie, malignancy).
Although not a commonly used modality, studies continue to show the utility of intravenous pulse cyclophosphamide. Wallace and Sherry [42] demonstrated that four patients with severe systemic-onset JRA benefited from 12-20 intravenous pulses of cyclophosphamide (and methylprednisolone). All the patients were able to discontinue corticosteroid use and all had an increase in linear growth, with three quarters achieving remission. The authors point out that this therapy is only to be considered in patients with very severe, destructive, persistent systemic-onset JRA.
Autologous stem cell transplantation is another controversial and life-threatening treatment offered at a few centers worldwide to treat childhood autoimmune disease, including JIA. There continues to be a high mortality rate associated with this therapy and the efficacy is unclear. A comprehensive review of the international experience with ASCT to treat JIA reported 4 fatalities among 26 children treated [43] .
Conclusions
The past 2 years have produced new and important information about the pathophysiology and treatment of juvenile arthritis. The development of etanercept remains a fine example of translational research, as pure biomedical research is transformed into a therapeutic agent to the immediate benefit of children and adults with chronic inflammatory arthritis. The new classification scheme for JIA may be a step forward in categorizing patients with JIA, allowing clinicians and scientists to communicate on an international level, but clinical validation is still lacking. Despite the advances, there is still much work to be done. Determining the causes of juvenile arthritis, developing targeted therapies, and eventual cure and prevention, remain the ultimate goal.
